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1. Introduction
Invasive primary malignant melanoma in whites shows the
greatest and most rapid increase of all cancer worldwide. The
incidence in South Africa is unknown but what is known is
that the incidence in the Cape Town area is similar to that in
Australia (24.4 per 100 000), and epidemiological studies to
determine the exact incidence are in progress. In Australia it is
one of the most common cancers1-3 with the estimated risk of
developing a melanoma before the age of 75 (in 1993) being 1
in 27 for males and 1 in 36 for females.3
Melanoma is therefore an important clinical and health
problem and it is essential that the management of the disease
is as effective as possible. This clinical practice guideline is
designed to assist those involved in the management of this
common cancer to provide optimal management for their
patients. It is based on the guideline developed and published
by the Australian Cancer Network4 and has been summarised
and adapted as follows.
2. Prevention
Exposure to sunlight is strongly associated with the
development of melanoma.5
The pattern of exposure is important, with intermittent
exposure being more closely linked to the development of
melanoma than the regular patterns of exposure of the outdoor
worker.5 The action spectrum that is causative for melanoma,
in particular the relative roles of UVB and UVA, is as yet
unknown. However, in animal models UVA has been found to
be a highly significant component in melanoma induction.6,7
In addition, the use of sunbeds, which deliver mainly UVA
radiation, may be a risk factor for melanoma.8
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Objective. 
1. The Guideline for the Management of Melanoma has been
developed in an attempt to improve management through
the process of locating the best available evidence on
which to base decisions. It is expected to help to improve
the quality of care.
2. Melanoma remains a common cancer in South Africa.
Despite the achievement of earlier diagnosis, it would
appear from current statistics that at least 850 people
continue to die of melanoma each year. Many of these
deaths occur at a younger age than for other solid tumours,
so the number of years of life lost due to melanoma
exceeds that of many other cancers.  It is seen as
imperative to maximise effective management of
melanoma.
3. Prevention of melanoma has not yet been achieved, and
there are no conclusive data to show that current
promotion of sun avoidance has substantially altered its
incidence.
4. Early detection is an important factor in melanoma
management, with diagnosis based mainly on changes in
colour, diameter, elevation and border (irregularity of
outline) of a skin lesion, asymmetry of a lesion, or a lesion
different from other naevi.  People at high risk of
melanoma should be offered a surveillance programme.
Recommendations.
1. All clinicians should be trained in the recognition of early
melanoma.
2. If there is doubt about a lesion, the patient should be
referred for specialist opinion (if readily available) or a
biopsy should be undertaken. Biopsy of a pigmented lesion
should be done only on the basis of suspicion of
melanoma. Excision with a 2 mm margin is adequate.
3. Prophylactic excision of benign naevi is not recommended.
In general, elective lymph node dissection is not indicated.
4. People with high-risk primary melanoma, lymph node
involvement and melanoma in unusual sites (e.g. mucosal
and disseminated melanoma) should be managed with
support from a melanoma centre.
Validation. Melanoma management involves many medical
specialties.  Guidelines should therefore be developed through
a multidisciplinary consensus. The Melanoma Advisory Board
consists of a forum of dermatologists, oncologists, plastic
surgeons and pathologists.
Guideline sponsor. The meetings of the Melanoma Advisory
Board are sponsored by Schering-Plough.
S Afr Med J 2004; 94: 697-708.
The following protection measures are recommended:
• Physical protection should be the primary preventive
measure. Avoid direct exposure to sunlight during the 2
hours either side of solar noon.
• Use sun-protective clothing when exposed to direct
sunlight for periods greater than 15 minutes.
• People should be advised to choose dark clothing of
closely woven fabrics, which is more protective than light
loosely woven garments.  Fabrics with an inbuilt
protection factor are available in sports/diving/climbing
shops.
• Use broad-spectrum sunscreens as an adjunct to sun
avoidance and other sun protective measures.  New
sunscreens should contain a UVA as well as UVB screen
and in contrast to previous recommendations that a factor
15 sunscreen is adequate the advice is the higher the
factor the better (> SP30).
• Provide and use sun-protective structures (e.g. shade
structures) whenever possible.
• Provide children with appropriate sun protection for
outdoor activities. Emphasis should be placed on the
protection of children and adolescents from excessive
sunlight exposure.9 Sunlight exposure at this age is
closely related to the development of naevi. The presence
of multiple naevi is a strong risk factor for melanoma.10-14
• Advise against the use of sunbeds, tanning booths and
tanning lamps. These deliver mainly UVA radiation, and
UVA radiation causes DNA mutation which is a
predisposing factor for subsequent carcinogenic UVB
damage. 
3. Clinical diagnosis of melanoma
The dignosis of melanoma should be considered in all cases of
pigmented or changing lesions on the skin.
The key to the clinical diagnosis of a pigmented melanoma
is irregularity of the lesion.  Irregularity of colour is most
important and the presence of a variety of colours in any one
lesion is a key feature.  While a black or blue/black colour is
the most common, many other shades of brown, blue, red, grey
or white are often seen.  Irregularity of outline is the second
most common feature with indentations and outgrowths
around the lesion often apparent.  Irregularity of the surface is
another important sign.
Amelanotic melanoma is clinically difficult to diagnose,
usually appearing as an enlarging smooth reddish nodule or
patch.  Sometimes an area of brown  pigment can be discerned
in these lesions.  Surface microscopy may be helpful.
The ABCDE system of diagnosis of melanoma has gained
general support.15,16
A = ASYMMETRY
A lesion is asymmetrical if opposite segments of the lesion are
appreciably different.
B = BORDER
The border of a melanoma is usually irregular, resembling a
coastline with bays and promontories around the edge. All or
part of the border is often well defined, in contrast with the
dysplastic naevus, whose border is often ill-defined and fades
into the background of the surrounding tissues.
C = COLOUR
Variation in colour is an important feature. A narrow red halo
is sometimes seen around the edge of a melanoma. It is
important to remember that amelanotic melanoma will have
little or no distinguishing colour.
D = DIAMETER
Superficial spreading melanomas are often greater than 
6 mm in diameter when first diagnosed, but it is possible to
diagnose smaller melanomas, particularly nodular lesions,
which appear not only as small shiny dark nodules but can
also be reddish in amelanotic forms.
E = ELEVATION
While E designates elevation, it is important to diagnose
melanoma while it is flat or with marginal elevation. At that
stage the lesion is more likely to be curable. Thus E should
remind the clinician to examine the patient’s other pigmented
lesions. 
A feature which may be helpful in diagnosing melanomas is
a ‘ground glass’ amorphous appearance to part of the lesion.
Where the skin lines have been destroyed by the tumours, a
shiny, glassy appearance is noted. Many melanomas will also
have small flakes of keratin on the surface, but it is extremely
rare for the lesion to be extensively keratinised. The presence of
hairs does not exclude a diagnosis of melanoma, but most
pigmented lesions with hairs are benign. However, more
advanced melanomas will not have hair in the deeply invasive
parts of the tumour because the melanoma will destroy the
hair follicles as it invades. Thick melanomas are firm to touch
and not compressible, unlike haemangiomas, and are rarely
waxy to feel, unlike a seborrhoeic keratosis. 
The differential diagnosis of pigmented melanoma includes
dysplastic naevus, Spitz naevus, pigmented basal cell
carcinoma, blue naevus, haemangioma, pigmented seborrhoeic
keratosis and some rare adnexal tumours. In children,
pigmented Spitz naevus is a likely diagnosis. 
The amelanotic or hypomelanotic tumour differential
diagnosis includes dermatofibroma, desmoplastic melanoma,
basal cell carcinoma and other spindle cell tumours.
• Good lighting and magnification is recommended when
lesions are being examined.
• All clinicians should become trained in the recognition of
early melanoma.
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• A good clinical history of change in the lesion, if any, a
past history of skin lesions, and a family history of
melanoma should be obtained. A family history is defined
as melanoma in a direct line family member —
grandparent, parent, sibling or child of the patient.
• Refer for a specialist opinion or biopsy lesions which are
suspicious.
• High-risk individuals should be advised on the specific
changes which suggest melanoma and encouraged to
undertake self examination. 
• Take note of any recent change or sensation reported by
the patient.
4.  Surface microscopy
• Skin surface microscopy should be carried out by specialists
who have had specific training and are experienced, owing
to the highly specialised nature of this examination
(dermatoscope).17-21
• Digital epiluminescence microscopy (Molemax®) can be
used to monitor high-risk patients because it allows viewing
of morphological features (colours, pigmentation pattern)
not seen with traditional surface microscopy and is an
effective documentation system.
5.  Screening and surveillance
Risk factors for development of melanoma include a family
history of melanoma, a fair complexion, a tendency to burn
rather than tan, the presence of freckles, the presence of solar
lentigines, light eye colour, light or red hair colour and a past
history of non-melanoma skin cancer.22-24
All individuals who are at high risk for the development of
melanoma should be advised about the changes that might
suggest the development of an early melanoma, encouraged to
undertake regular self-examination and advised regarding
appropriate methods of sun protection. 
The presence of large numbers of melanocytic naevi and the
presence of clinically determined atypical or dysplastic naevi
are very strong risk factors for melanoma.13, 22-25 Dysplastic naevi
are generally larger than normal moles with ill-defined edges
and irregular pigmentation, mostly shades of brown.26 They
tend to have a poorly defined edge.26 Melanoma risk increases
with increasing numbers of total naevi and dysplastic naevi.13,22-25
The risk associated with clinical dysplastic naevi has been
shown to be independent of that associated with the total
numbers of naevi.25 Clinically dysplastic naevi are not always
dysplastic on histopathological examination. 
Prophylactic excision of dysplastic naevi and other benign
naevi is not useful in minimising melanoma risk.  A significant
proportion of melanomas begin as new lesions rather than
developing from pre-exsiting naevi.27-29
Consider referral of these high-risk individuals to a
specialist with an interest in melanoma management.
6.  Familial risk and family surveillance
Recent Australian data indicate that 10% of patients with
melanoma will have at least one confirmed melanoma-affected
first-degree relative,30 potentially resulting from inheritance of
uncommon, major melanoma susceptibility gene(s).31
Consider referral of family members with a strong history of
melanoma among close relatives, particularly those with large
numbers of naevi, to a specialist with interest in melanoma
management and refer for genetic studies if available.
7. Biopsy of pigmented lesions
• Biopsy of pigmented lesions should be done only on the
basis of suspicious clinical features. Prophylactic excision
of clinically benign lesions is not recommended.  Primary
biopsy should always be performed by complete excision.
• Shave and punch biopsies of pigmented lesions should be
avoided.
• Lesions suspected to be melanoma should be excised with
a 2 mm lateral margin and to the depth of the upper layer
of the fat.
• Where doubt exists, a period of observation based on the
history and clinical features of the lesion is acceptable.
The period of observation will be short if a high level of
suspicion of melanoma is present. However, if the
clinician considers that the lesion is unlikely to be
melanoma and it does not change, it is appropriate to
continue observation until evidence of change appears.
• If melanoma is suspected, referral for a specialist opinion,
where available should be considered before biopsy is
undertaken.
8. Congenital melanocytic naevi
Congenital naevi are present at birth and are diagnosed with
specific histological features.32-34 The lesions are arbitrarily
divided into three groups based on diameter: < 1.5 cm, 1.5 - 20
cm and ≥ 20 cm. 
Small (< 1.5 cm) lesions occur in 1% of births.  They are not
thought to have an increased malignant potential.29-34
Medium (1.5 - 20 cm) lesions have not been subject to
adequate research so the malignant potential of this group is
unclear.35,36 If excision is undertaken, it should be during the
teenage years, since a study of 31 patients with melanomas
arising from small congenital naevi (1.5 - 10 cm) found none of
these melanomas presenting before puberty. However, at this
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stage the body of evidence suggests that observation only is
required. 
Large (> 20 cm) lesions. There are only two prospective
studies addressing these lesions. These show a crude risk of
3%.37-39 A literature review8 has shown that 70% of melanomas
in this group develop before puberty. 
Superficial removal of the naevus by dermabrasion or
tangential excision is not recommended as two-thirds of
melanomas develop in non-epidermal sites.40,41
Patients with large congenital naevi of the head and neck are
also at risk from neurocutaneous melanosis.42
Magnetic resonance imaging (MRI) scan should be
considered for screening these patients.43 Lifelong surveillance
for large and possibly for medium congenital naevi is
recommended. 
• Excisional biopsy of suspicious areas in large congenital
naevi is recommended but should be carried out at a
specialist centre.
• Surgical excision of congenital naevi is appropriate where
patient concern is high and where an acceptable cosmetic
outcome can be achieved. The removal of large naevi for
cosmetic reasons only has no contraindications provided the
patient is made fully aware of the likely appearance of the
end result.
9. Lentigo maligna
Lentigo maligna (Hutchinson’s melanotic freckle) is a common
pigmented lesion on the exposed skin of the older patient.
These lesions are regarded as in situ melanoma and may
progress to invasive melanoma (lentigo maligna melanoma) in
many people, and so must be managed carefully. These lesions
occur predominantly on the face. 
• Biopsy is indicated for changing pigmented lesions on the
face.
• Where lentigo maligna is histologically confirmed,
complete excision is the preferred management.
• For some patients, treatment by observation for change,
with measurement, is an acceptable alternative to
immediate excision.
• A Wood light is helpful to determine the extent of the
lentigo maligna.
• Cryotherapy and shave biopsies should be left to the
discretion of a specialist.
10. Histopathological report
An accurate histopathology report is an essential prerequisite
for optimal therapy for melanoma. 
• Request forms for pathology should include adequate
patient identification, and clinical details of all lesions removed.
• Where more than one lesion is excised, separate specimen
bottles are essential.
• The pathologist’s report should include all important
features of the lesions (histopathological type, tumour
thickness and ulceration).
• Tumour thickness, ulceration and clearance margins are
essential. A standardised format of histological reporting on
melonoma is advocated.
• Where clinical and pathological diagnoses do not concur, a
second opinion should be sought from a pathologist with
expertise in the diagnosis of pigmented tumours.
11. Classification of melanoma
Use of the American Joint Committee on Cancer (AJCC) and
Union against Cancer Committee (UICC) classification system
(2002) is recommended.44
The primary tumour categories in the TNM classification are
based on two microstaging systems. The Clark system
describes the level of micro-invasion through the layers of the
dermis.  This is now mainly of historic value and relevant only
for very thin melanomas.  It has been replaced by the Breslow
thickness, which is considered the most important diagnostic
factor for primary melanoma.  The thickness is measured in
millimetres from the granular cell layer to the base of the lesion
and is divided into four groups:
• < 0.75 mm
• 0.75 - 1.50 mm
• > 1.50 - 4 mm
• > 4 mm.
11.1 Primary tumor (T)45
TX Primary tumour cannot be assessed (e.g. shave biopsy or
regressed melanoma)
T0 No evidence of primary tumor
Tis Melanoma in situ
T1 Melanoma   ≤ 1.0 mm in thickness, with or without
ulceration
T1a Melanoma   ≤ 1.0 mm in thickness and level II or III, no
ulceration
T1b Melanoma   ≤ 1.0 mm in thickness and level IV or V, with
ulceration
T2 Melanoma   1.01 - 2 mm in thickness, with or without
ulceration
T2a Melanoma   1.01 - 2.0 mm in thickness, no ulceration 
T2b Melanoma   1.01 - 2.0 mm in thickness, with ulceration
T3 Melanoma   2.01 - 4 mm in thickness, with or without
ulceration
ORIGINAL ARTICLES
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T3a Melanoma   2.01 - 4.0 mm in thickness, no ulceration
T3b Melanoma   2.01 - 4.0 mm in thickness, with ulceration
T4 Melanoma > 4.0 mm in thickness, with or without
ulceration
T4a Melanoma > 4.0 mm in thickness, no ulceration
T4b Melanoma > 4.0 mm in thickness, with ulceration.
N.B. Note that Clark level is only important for thin
melanomas (T1).
11.2 Regional lymph nodes (N)45
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in one lymph node
N1a Clinically occult (microscopic) metastasis
N1b Clinically apparent (macroscopic) metastasis
N2 Metastasis in two to three regional nodes or intra-
lymphatic regional metastasis without nodal metastases
N2a Clinically occult (microscopic) metastasis
N2b Clinically apparent (macroscopic) metastasis
N2c Satellite or in-transit metastasis without nodal metastasis
N3 Metastasis in four or more regional nodes, or mated
metastatic nodes, or in-transit metastasis or satellite(s)
with metastasis in regional node(s).
11.3 Distant metastasis (M)45
MX Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
M1a Metastasis to skin, subcutaneous tissues or distant lymph
nodes
M1b Metastasis to lung
M1c Metastasis to all other visceral sites or distant metastasis
at any site associated with an elevated serum lactic
dehydrogenase (LDH).
12. Treatment of primary melanoma
• The AJCC/UICC system (2002) is recommended as the
basis for melanoma therapy.45
• Complete excision with margins determined by tumour
thickness measurement should be the basis for
management of primary melanomas.
• A minimum margin of 1 cm and a maximum margin of 
3 cm should be used for invasive melanoma, with a choice
of excision margin determined by tumour thickness. A
depth of excision equal to the margin is advised but it is not
necessary to excise further than the deep fascia.
• Other pathological features should be used to make an
assessment of prognosis and modify management decisions.
In very thin lesions, thickness alone does not accurately
predict the prognosis.
The following is recommended:46-49
1. pTis Melanoma in situ margin 5 mm
2. pT1, pT2 Melanoma 0 - 1.5 mm margin 1 cm
3. pT3 Melanoma 1.5 - 4.0 mm minumum margin 1 cm
and maximum margin 2 cm
4. pT4 Melanoma > 4.0 mm minimum margin 2 cm
and maximum margin 3 cm
It should be noted that there is no evidence that a margin
greater than 1 cm offers additional benefit to the patient in
terms of survival, but it may decrease local recurrence.47-50
Primary lesions in special sites should be referred to a
specialist centre.
13.  Survival outcomes of primary
melanoma management
• Survival after diagnosis of melanoma falls with increasing
tumour thickness.51-52 To advise patients on the likely
outcome of their primary melanoma management, the
estimates in Table I may be given for 5-year survival rates
from the AJCC 2002:
• Other prognostic variables influence outcome. Such factors
as a thin melanoma which reaches Clark level 4, ulceration,
the presence of lymphatic invasion, satellites and high
mitotic rate may adversely affect the prognosis for the
individual patient with melanoma.53,54
14. Treatment of lymph nodes
All patients with invasive melanoma are at risk for metastases
to the lymph nodes. Metastases to lymph nodes are uncommon
for melanomas < 1.0 mm in tumour thickness. For primary
melanomas 1.0 mm and greater in thickness, an increasing
proportion of patients will develop regional lymph node
Table I. Five-year survival rates (%) of pathologically staged
patients (adapted from Balch et al.47)
IA IB IIA IIB IIC IIIA IIIB IIIC
Ta: Non- T1a T2a T3a T4a N1a, N1b, N3
ulcerated N2a N2b
melanoma 95 89 79 67 67 54 28
Tb: Ulcerated T1b T2b T3b T4b N1a, N1b,
melanoma N2a N2b,
N3
91 77 63 45 52 24
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involvement. At least 25% of patients with melanomas between
1.5 mm and 4.0 mm thick will have microscopic lymph node
involvement at the time of primary diagnosis. Sixty per cent of
melanomas thicker than 4.0 mm will have nodal involvement,55-
57 but these involved nodes are usually not clinically apparent
at the time of primary diagnosis.
• Needle aspiration is preferable to excision biopsy of
lymph nodes suspicious of metastatic melanoma.51 This
should only be performed by doctors who are thoroughly
familiar with the technique. If the local radiologist has
expertise in ultrasound of nodes then it may be appropriate
to do ultrasound and proceed directly to a block dissection
if nodes are suspicious.
• Excision biopsy of suspicious nodes should be followed
by immediate node dissection if nodal metastases are
detected.51
• Elective lymph node dissection is generally not
recommended.58-66
• Therapeutic node dissection should be undertaken only
by surgeons trained in these procedures.67-74
• The recent surgical technique of lymphatic mapping and
selective sentinel node biopsy provides an alternative
approach to the treatment of melanoma > 1 mm thick.69-71
Sentinel node biopsy means identification of the first lymph
nodes (the sentinel nodes) to take up radioactive tracer injected
around a primary site.  These nodes are then marked on the
skin and identified at surgery by injection of patent blue dye.
The blue-stained nodes are selectively biopsied and examined
by histology and immune histochemistry.  Should they be
positive the lymph nodes are dissected.  This ensures that
patients with nodal involvement are subjected to full regional
lymph node dissection.
Sentinel node biopsy should only be performed by surgeons
trained in this procedure.
Adequate node dissection is associated with a reasonably
good prognosis, with a 10-year survival of up to 50% where
only one node is involved. Even when two or three nodes are
involved, 10-year survival rates of up to 30% can be achieved.51
However, extranodal spread is associated with a high fatality
rate, and radiotherapy could be considered if this is detected, if
the nodes are extensively involved or if tumour spillage occurs
during the surgery.
• CT scans could be used to assess the iliac nodes where
inguinal lymph node dissection is contemplated.
15. Occult primary melanoma
• Melanoma in lymph nodes or systemic metastases should
be treated in accordance with guidelines regardless of
inability to detect the primary lesion.75-78
16. Locoregional recurrent melanoma
• Excision of a single local or regional metastasis is the
treatment of choice.
• Limb perfusion in a specialised centre should be considered
if satellite lesions are present.79-82
17. Adjuvant therapy
• Patients with melanomas > 4 mm thick or with lymph node
metastases should be referred to a specialised centre for
consideration for adjuvant therapy.
18. Disseminated melanoma
• Patients with systemic metastases should be referred to a
specialised centre for consideration for systemic therapies.
• All clinicians dealing with patients with systemic melanoma
should be appropriately skilled in psychological
management and palliative care.83-85
• Surgical resection should be considered for isolated
melanoma metastases in lung, brain and peritoneal cavity.86
Multiple subcutaneous metastases may be well controlled
with surgery in some cases if the patient is followed up
carefully.
19. Radiotherapy for melanoma
• Postoperative radiotherapy could be considered for
cutaneous melanomas likely to recur, e.g. where wide
resection of the primary tumour is not feasible, as
sometimes happens on the face87 or regionally (multiple
node involvement or extra-capsular spread) and following
resection of mucosal melanomas. 
• Primary radiotherapy should be considered for unresectable
lentigo maligna melanomas or large unresectable primary
lesions in the elderly and frail.87
• Radiotherapy may be recommended for treatment of
extensive cutaneous metastases where surgery is not
feasible and for palliative management of cerebral and bone
metastases and for other metastases where temporary local
control is needed, e.g. large nodal or soft-tissue masses.88-91
20. Palliative care
• Educating patients and carers as to the behaviour of
metastatic melanoma with its unique features (i.e.
subcutaneous spread and acute episodes of pain due to
bleeding) and the appropriate intervention will assist them
in coping with the disease.
• Clinicians should be aware of the palliative care services
available within the patient’s community, so that referral
ORIGINAL ARTICLES
can be made if the patient so wishes.
21. Follow-up
• A follow-up regimen based on tumour thickness should
be arranged for all patients with melanoma.92,93
• The follow-up examination should include palpation for
local recurrence, in-transit and lymph node metastases
and signs of systemic relapse. A general examination of
the skin for new primary melanomas and other skin
cancers should be performed.
22. Appropriate investigations
• Extensive investigation for systemic metastases in patients
with primary melanoma is not recommended.94-96 Baseline
investigations such as a full blood count, chest radiograph
and liver functions, including LDH, may be undertaken.
Patients with deep lesions should have a computed
tomography (CT) scan of the chest and upper abdomen.
The latter may serve as a baseline for future comparison.
• Generally investigations such as MRI and PET (positron
emission tomography) should be utilised only where
specific symptoms suggest the presence of metastases.
23. Specific sites and types of
melanoma
23.1 Mucosal melanoma
Mucosal melanoma is rare, comprising < 1% of all melanomas.
It occurs in the mouth, nose, oesophagus, gallbladder, urethra,
anus, vulva and vagina, and is usually asymptomatic.97,98 For
this reason mucosal melanoma is generally detected late and
thus has a very poor prognosis..99
Patients with mucosal melanoma should be referred to a
suitable specialised clinic or clinician.
23.2 Acral lentiginous melanoma (ALM)
ALM is defined as melanoma of the acral skin, i.e. the
thickened skin of the soles and palms. The main interest of the
ALM classification is that it is the predominant melanoma of
non-white individuals. Its prognosis may be marginally worse
than other melanomas but this is yet to be conclusively proven. 100-102
ALM on the sole of the foot should be referred for specialist
excision and appropriate reconstructive procedures and
therapies.
23.3 Subungual melanoma
Subungual melanoma should be considered as a possible cause
of any pigmentary changes under the nail.103 In cases of doubt,
removal of the nail and biopsy is recommended.104-106 Subungual
melanoma should be treated with excision margins that accord
to the lesion thickness.  This usually involves amputation of
the terminal phalanx.104
Because most subungual melanomas are advanced at the
time of presentation, elective node dissection may be
appropriate for these patients.107,108
Naevi on the soles of the feet or on the genitals should not be
removed routinely, because the incidence of malignant
transformation of the these lesions is not higher than that of
other lesions.
23.4 Desmoplastic melanoma
Desmoplastic and neurotropic melanomas are associated with a
high risk of local recurrence related to their poorly defined
clinical borders, frequent amelanosis and infiltration along
nerve sheaths, predisposing to incomplete excision and
persistence of the primary tumour.109,110
Wider excision than is normal for other histological types of
melanoma is recommended for desmoplastic melanoma.
Postoperative radiotherapy in consultation with a specialist
should be considered after surgical excision of a recurrent
desmoplastic or neurotropic melanoma.
23.5 Multiple primary melanoma
Multiple new primary melanomas may occur in at least 5% of
patients with melanoma.111-113 They are more common in
patients with multiple atypical naevi, especially in a familial
melanoma setting, but can occur in any patient who has had a
melanoma.114,115
Multiple primary melanoma should be treated according to
the tumour thickness of each lesion.116
23.6 Melanoma in childhood
Melanoma is rare in children below the age of 12, but clinical
features are identical to those in the adult.116
Melanoma in children should be treated as appropriate for
the same tumour thickness as melanoma in the adult.117,118
23.7 Melanoma during pregnancy
Melanoma in a pregnant woman should be treated according
to the tumour thickness.119-121 It has not been conclusively
demonstrated that pregnancy alters the prognosis in a patient
who has a melanoma diagnosed either before or during
pregnancy. 120 Pregnant women with thicker melanomas and
nodal metastases should be treated in consultation with
specialised centres and psychological support may need to be
obtained.
Because of the possibility of metastatic recurrence, pregnancy
is not advisable for 2 years after removal of high-risk primary
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melanoma or melanoma in nodes.122
Termination of pregnancy should be considered in women
with high-risk primary or recurrent melanoma only after
detailed discussion with the patient and her partner.
23.8 Hormone replacement therapy and oral
contraceptives
Hormone replacement therapy and oral contraceptives are not
contraindicated for women who have or have had
melanoma.123,124
24. Disclaimer 
This document is a general guide to appropriate practice, to be
followed only subject to the clinician’s judgement in each
individual case.  It was compiled by members of the Melanoma
Advisory Board, a multidisciplinary forum consisting of
Dermatologists, Oncologists, Plastic Surgeons and Pathologists.
The guideline is designed to provide information to assist
decision making and was based on the best information
available at the date of compilation (November 2003).
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